In a Move to Accelerate Transparency and Development in the Diamond Industry, CEDEX and IDEX Online Join Forces
Under the agreement, CEDEX will leverage on IDEX diamond knowledge and real-time diamond prices to present it to its future exchange customers, while IDEX will use CEDEX technology to better accommodate investments in the diamond professional market.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171127005483/en/
With over two decades of undisputable reputation as a prominent and unbiased market leader in the diamond industry, IDEX moves to strongly reinforce CEDEX technological innovations. “We believe that the diamond industry stands to gain by connecting with CEDEX B2C offerings, vision, and trading models. The integration into the financial world and the transformation of diamonds into a new financial asset class have been a key driving force behind IDEX’s activity since the company’s establishment. Joining forces with CEDEX enables us to better serve our diamond suppliers and traders” says Ehud Cohen, Founder and Chairman of IDEX Online. “There is no doubt that harnessing IDEX’s diamond suppliers’ data and inventory is a pivotal step forward towards connectivity between the diamond industry and the financial market” says Ronen Priewer, founder of CEDEX. “By providing analysis driven from the largest available database of B2B diamond transaction records, IDEX enables our proprietary technology, the DEX, to achieve accurate and scientific results making it a unique diamond value benchmark for any financial need. CEDEX which fosters usage of Cryptocurrency CEDEX coin to enable trading in diamonds is targeting to enlarge the offering through collaboration with IDEX online.
Both companies complement themselves, as IDEX is a B2B reality, while CEDEX is B2C. This creates new opportunities for both companies, enabling mutual methodological advice and benefits deriving from the markets that the companies cover. This move sets both companies to enlarge into the emerging new economy system.
CEDEX is the First Certified Blockchain Based Diamond Exchange.
CEDEX.com is a global exchange that focuses on bridging the gap between the traditional diamond industry and the innovative financial markets. With its extensive industry knowledge, CEDEX wants to engineer a ground-breaking change – enabling people to liquidate and trade in diamonds like any other financial asset, in a transparent and secure way.
The CEDEX exchange will enable trading on individual diamonds, shares in a high- value stone or shares in a basket of diamonds (ETF). Through the DEX, CEDEX’s machine learning algorithm and blockchain technology that rates and evaluates diamonds’ prices, traders, buyers and sellers will have full confidence in investing on the platform.
The CEDEX project was founded by a team of professionals in technology (trading platforms and pricing engines), financial markets and the diamond industry.
About IDEX Online
IDEX - International Diamond Exchange - is the leading online diamond-trading platform for professional diamond traders located in the main diamond cities such as Antwerp, Mumbai, Ramat Gan and New York.
IDEX reach into the professional diamond trade is comprehensive - more than 7,000 professional traders use the system regularly; more than 75% of the supply chain inventory is featured on the system. IDEX is a leader and innovator in diamond pricing products and its prices and data has become one of the industry standards. The widely used and followed IDEX Diamond Index has been published continuously since 2004 and is the first and oldest index based on actual listing data.
CEO & Co-Founder
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 16:00 | Tiedote
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice
Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 15:47 | Tiedote
The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i
Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 13:18 | Tiedote
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,
Dr Amal Al Qubaisi Wins Parliamentarian Excellence Award as Best President of Arab Parliament11.12.2017 12:41 | Tiedote
The Arab Inter-Parliamentary Union (AIPU) has honored Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the United Arab Emirates parliament, with the Parliamentarian Excellence Award in the Presidents of Arab Parliaments category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005411/en/ Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the UAE parliament (Photo: AETOSWire) The award honors Al Qubaisi as ‘first female leader of a parliament in the Arab world’, celebrating her achievements on a national, regional and global scale, as well as the accomplishments made by FNC under her leadership. It also acknowledges the pioneering parliamentarian initiatives, projects and programs she has spearheaded and her significant contr
Top UK university hospital unveils data that support the use of rapid infusion for Truxima® (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma11.12.2017 11:00 | Tiedote
New data from University College London Hospitals NHS Foundation Trust (UCLH) on the safety and tolerability of rapid infusion of CT-P10 were presented this weekend at the 59th American Society of Hematology (ASH) Annual Meeting. The results showed that rapid infusion of CT-P10 was well-tolerated across all patient groups and patients could be safely switched from reference rituximab to CT-P10 without reverting to slower infusion rates1. The independent study examined the infusion-related reactions (IRRs) in three different patient groups: rituximab naive, those switching directly from reference rituximab to CT-P10, and those that received their last dose of reference rituximab at least 6 months prior to the study.1 The administration of rituximab is associated with IRRs which occur most frequently during the first infusion. To reduce the risk of IRRs, it is the man
Financial Market Regulator Grants EU Payment License to DIMOCO Payment Services11.12.2017 11:00 | Tiedote
The Austrian Financial Market Authority (FMA) granted a license under the Payment Service Act to DIMOCO Payment Services . The awarded license allows DIMOCO Payment Services to contribute to the payment value chain, offering merchants a single technical interface and a unified clearing & settlement process for many payment methods, including credit cards, online bank transfers, SEPA and direct debit cards. “We differ from most PSPs in the global payments ecosystem with our personal touch,” said Boris Kersten, Managing Director of DIMOCO Payment Services. “We proactively and personally monitor the overall payment process. In addition to monitoring individual transactions, we make recommendations and take actions to decrease chargebacks and fraudulent transactions. This process is not simply left to algorithms, the human element is added to the mix resulting in the protec
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme